Research programme: cancer therapeutics - Synlogic/RXi

Drug Profile

Research programme: cancer therapeutics - Synlogic/RXi

Alternative Names: RNAi-based cancer therapies - Synlogic/RXi Pharmaceuticals

Latest Information Update: 10 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mirna Therapeutics; RXi Pharmaceuticals Corporation
  • Developer Mirna Therapeutics; RXi Pharmaceuticals
  • Class Small interfering RNA; Small molecules
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Liver cancer

Most Recent Events

  • 02 Aug 2018 RXi Pharmaceuticals has patent protection for sd-rxRNA platform in European Union and Japan
  • 28 Aug 2017 Synlogic has merged with Mirna Therapeutics forming Synlogic
  • 02 May 2016 RXi Pharmaceuticals has patent protection for sd-rxRNA® platform in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top